Drugs / Vacc-C5
Vacc-C5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01627678 | Sep 2012 → Nov 2013 | HIV infectious disease | Bionor Immuno AS | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2016-09-21 | Bionor Immuno AS | Results Poster presentation at the 18th Institute of Human Virology Annual Conference bionorholding.com ↗
The findings to date support the hypothesis that anti-Vacc-C5 antibodies may play a role in reducing unwanted immune activation in HIV infection. |
| 2014-02-24 | Bionor Immuno AS | Results Positive Results from Bionor Pharma’s vaccine Vacc-C5 Phase I, First Time in Man trial bionorholding.com ↗
The trial met its primary endpoint which was safety. |
| 2013-04-05 | Bionor Immuno AS | Results Bionor Pharma`s Hypothesis for Immune Activation Mediated by the C5 Region of HIV Presented at Scientific Conference bionorholding.com ↗
These data support the concept behind Bionor Pharma`s vaccine candidate Vacc-C5, which is designed to induce antibodies to the C5 region (of gp120) of the virus to reduce the hyperactivation that eventually overwhelms the immune system of most HIV-infected individuals. |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-10-01 | Bionor Immuno AS | New strategy for combining Vacc-4x and Vacc-C5 with a defined path that can lead to a regulatory approval and commercialization bionorholding.com ↗ |
| 2017-03-24 | Bionor Immuno AS | Vacc-C5 phase I/II clinical study published in BMC infectious diseases bionorholding.com ↗ |
| 2016-09-21 | Bionor Immuno AS | Poster presentation at the 18th Institute of Human Virology Annual Conference bionorholding.com ↗ |
| 2014-02-24 | Bionor Immuno AS | Positive Results from Bionor Pharma’s vaccine Vacc-C5 Phase I, First Time in Man trial bionorholding.com ↗ |
| 2013-05-27 | Bionor Immuno AS | Patient Enrollment Completed in Bionor Pharma’s First Human Clinical Study of the HIV Vaccine Vacc-C5 bionorholding.com ↗ |
| 2013-04-05 | Bionor Immuno AS | Bionor Pharma`s Hypothesis for Immune Activation Mediated by the C5 Region of HIV Presented at Scientific Conference bionorholding.com ↗ |
| 2012-05-29 | Bionor Immuno AS | First Human Study of HIV Vaccine Vacc-C5 to begin bionorholding.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vacc-C5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01627678 ↗ |
| Known as | Vacc-C5 = C5-pepide | “Vacc-C5 = C5-pepide” NCT01627678 ↗ |
| Known as | Vacc-C5 = C5-peptide | “Vacc-C5 = C5-peptide” NCT01627678 ↗ |
| Modality | Vaccine | “Vacc-C5, a peptide-based therapeutic vaccine candidate corresponding to C5/gp41732-744” PMID 28340570 ↗ Mar 2017 |
| Route | Other | “Vacc-C5 with GM-CSF as adjuvant administered intradermally.” NCT01627678 ↗ |